Abstract Number: 1374 • 2017 ACR/ARHP Annual Meeting
Flares in Patients with Rheumatoid Arthritis Are Strongly Associated with Worse Clinical Outcomes but Are Difficult to Predict
Background/Purpose: Disease flares in RA are associated with radiographic progression1 and functional deterioration2. Predicting flare is of direct relevance to clinical practice, particularly in patients…Abstract Number: 1388 • 2017 ACR/ARHP Annual Meeting
Fatigue Is Strongly Associated with the Patient Global Assessment and May Affect Disease Severity and Clinical Remission in Patients with Rheumatoid Arthritis: A Cross-Sectional Study from IORRA, a Large Observational Cohort of Japanese Rheumatoid Arthritis Patients
Background/Purpose: Fatigue is a common complaint in patients with rheumatoid arthritis (RA)1. However, its impact on disease activity and clinical remission in patients with RA…Abstract Number: 1446 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Serum Levels of ROM (reactive oxygen metabolities) at 12 Weeks during Treatment with Biologic Agents As a Predictor for the 52-Week Remission
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…Abstract Number: 1449 • 2017 ACR/ARHP Annual Meeting
Development of a Predictive Score of Successful TNF Inhibitor Tapering in Patients with Rheumatoid Arthritis Remission
Background/Purpose: Tapering trials confirmed the feasibility of TNF inhibitors (TNFi) tapering for a relevant proportion of patients in remission and/or low disease activity. However, there…Abstract Number: 1460 • 2017 ACR/ARHP Annual Meeting
Predictive Factors Associated with Successful Down-Titration of Biologics for Rheumatoid Arthritis Patients in Clinical Practice
Background/Purpose: Randomized clinical trials have shown that if a patient is in sustained remission, biological disease-modifying anti rheumatic drugs (bDMARDs) therapy can be tapered in…Abstract Number: 1797 • 2017 ACR/ARHP Annual Meeting
Insights from Treating to Target in Rheumatoid Arthritis at an Academic Medical Center
Background/Purpose: Current RA guidelines recommend treating to a target of remission or low disease activity (RM/LDA) state. In a prior quality improvement (QI) project, our…Abstract Number: 2434 • 2017 ACR/ARHP Annual Meeting
Baseline Expressions of Cellular microRNA-31 and microRNA-10a Predict Remission and Low Disease Activity in Patients with Early Rheumatoid Arthritis after Six and Twelve Months of Therapy
Background/Purpose: MicroRNAs (miRNAs) post-transcriptionally regulate gene expression by targeting messenger RNAs. The expression of miRNAs was demonstrated to differ between patients with rheumatoid arthritis (RA)…Abstract Number: 518 • 2016 ACR/ARHP Annual Meeting
Contribution of Patient Global Assessment on Loss and Gain of Disease Remission in Patients with Established Rheumatoid Arthritis in Clinical Practice
Background/Purpose: Patient global assessment (PGA) is part of the remission definitions in Rheumatoid arthritis (RA). We explored the proportion of patients who fail to achieve…Abstract Number: 2587 • 2016 ACR/ARHP Annual Meeting
The Serum Level of Reactive Oxygen Metabolities (ROM) at 12 Weeks during Treatment with Biologic Agents for Rheumatoid Arthritis Is a Predictor for the 52-Week Remission
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…Abstract Number: 534 • 2016 ACR/ARHP Annual Meeting
Discordance Between Physician-Stated Remission and 28-Joint Disease Activity Score (DAS28)-Defined Remission in Rheumatoid Arthritis Patients
Background/Purpose: Data were drawn from the 2014 Adelphi RA Disease Specific Programme in 5 European countries (France, Germany, Italy, Spain, UK). Rheumatologists provided details about…Abstract Number: 2621 • 2016 ACR/ARHP Annual Meeting
Incremental Benefit of Radiographic Inhibition on Long-Term Outcomes in Patients with Rheumatoid Arthritis
Background/Purpose: For the treatment of rheumatoid arthritis (RA) a therapeutic window of opportunity exists– patients treated early have favorable outcomes compared with patients treated after…Abstract Number: 545 • 2016 ACR/ARHP Annual Meeting
Utility of Power Doppler Ultrasound-Detected Synovitis for the Prediction of Short Term Flare in Rheumatoid Arthritis Patients in Clinical Remission
Background/Purpose: Ultrasound has been shown to detect subclinical synovitis in patients who are in clinical remission, in rheumatoid arthritis (RA). The value of power Doppler…Abstract Number: 2647 • 2016 ACR/ARHP Annual Meeting
Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
Background/Purpose: To determine predictive factors of disease flares, including drug trough serum levels and anti-drug antibodies (Ab) in patients with rheumatoid arthritis (RA) or polyarticular…Abstract Number: 555 • 2016 ACR/ARHP Annual Meeting
HAQ Score Is an Independent Predictor of Sustained Remission in Patients with Rheumatoid Arthritis
Background/Purpose: We compared remission rates, according to different definitions of remission in rheumatoid arthritis (RA) and investigated the potential predictors of sustained remission at the…Abstract Number: 3085 • 2016 ACR/ARHP Annual Meeting
Do Depression and Anxiety Reduce the Chance of Remission in Rheumatoid Arthritis and Psoriatic Arthritis?
Background/Purpose: Depression and anxiety are reported to predict poorer treatment outcomes in rheumatoid arthritis (RA).1 Whether this can be confirmed in larger, prospective studies as…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 8
- Next Page »